Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 August 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer

This week's New England Journal of Medicine analyzed plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer.

News image

Circulating cell-free Epstein–Barr virus (EBV) DNA is a biomarker for nasopharyngeal carcinoma.

Dr Allen Chan and colleagues conducted a prospective study to investigate whether EBV DNA in plasma samples would be useful to screen for early nasopharyngeal carcinoma in asymptomatic persons.

The researchers analyzed EBV DNA in plasma specimens to screen participants who did not have symptoms of nasopharyngeal carcinoma.

Participants with initially positive results were retested approximately 4 weeks later, and those with persistently positive EBV DNA in plasma underwent nasal endoscopic examination and magnetic resonance imaging (MRI).

A total of 20,174 participants underwent screening.

Sensitivity of EBV DNA in plasma samples in screening for nasopharyngeal carcinoma were 97%
New England of Journal Medicine

The researchers found that EBV DNA was detectable in plasma samples obtained from 1112 participants, and 309 of all participants.

The team noted that 28% of those who initially tested positive had persistently positive results on the repeated sample.

Among these 309 participants, 300 underwent endoscopic examination, and 275 underwent both endoscopic examination and MRI.

Of these participants, the researchers found that 34 had nasopharyngeal carcinoma.

A significantly higher proportion of participants with nasopharyngeal carcinoma that was identified by screening had stage I or II disease than in a historical cohort, and had superior 3-year progression-free survival.

The researchers noted that 9 participants declined to undergo further testing, and 1 of them presented with advanced nasopharyngeal carcinoma 32 months after enrollment.

Nasopharyngeal carcinoma developed in only 1 participant with negative EBV DNA in plasma samples within 1 year after testing.

The team observed that sensitivity and specificity of EBV DNA in plasma samples in screening for nasopharyngeal carcinoma were 97% and 99%, respectively.

Dr Chan's team concludes, "Analysis of EBV DNA in plasma samples was useful in screening for early asymptomatic nasopharyngeal carcinoma."

"Nasopharyngeal carcinoma was detected significantly earlier and outcomes were better in participants who were identified by screening than in those in a historical cohort."

NEJM 2017; 377:513-522
11 August 2017

Go to top of page Email this page Email this page to a colleague

 22 August 2017 
Survival in patients with Lynch syndrome
 22 August 2017 
Improving the diagnostic accuracy of severe liver fibrosis in NAFLD
 22 August 2017 
New therapies to manage Hep B
 21 August 2017 
Treatments for chronic idiopathic constipation
 21 August 2017 
Improving medication adherence in IBD
 21 August 2017 
Ethnic disparities for chronic Hep C survival
 18 August 2017 
Proteomic analysis of IBD
 18 August 2017 
Pediatric intestinal failure
 18 August 2017 
Anti-TNF treatment and bowel resection in Crohn's
 17 August 2017 
Outcomes of ulcerative colitis patients undergoing pouch surgery
 17 August 2017 
Mortality in patients with asymptomatic pancreatic cystic neoplasms
 17 August 2017 
Survival after primary tumor resection in advanced colorectal cancer
 16 August 2017 
Assessment of seronegative villous atrophy
 16 August 2017 
Appendectomy and colectomy risk in ulcerative colitis
 16 August 2017 
Gluten sensitivity and celiac disease
 15 August 2017 
Infliximab and treatment failure during maintenance
 15 August 2017 
Genetic in idiopathic pancreatitis
 15 August 2017 
Genetic factors and tobacco in IBD
 14 August 2017 
Per oral endoscopic myotomy
 14 August 2017 
Early colonoscopy and symptomatic colorectal cancer
 14 August 2017 
Ethnic disparities and Hep C survival
 11 August 2017 
Ledipasvir and sofosbuvir in treatment-naďve Hep C
 11 August 2017 
EBV DNA to screen for nasopharyngeal cancer
 11 August 2017 
Direct acting antivirals and mixed cryoglobulinemia
 10 August 2017 
Routine preoperative laboratory tests for elective surgery
 10 August 2017 

Whole-genome sequencing in primary care

 10 August 2017 
Mortality in cirrhosis
 09 August 2017 
Anticoagulants in cirrhosis
 09 August 2017 
Low birthweight and pediatric NAFLD
 09 August 2017 
IBS with extraintestinal somatic and psychological symptoms
 08 August 2017 
Prior Barrett’s diagnosis and esophageal cancer survival
 08 August 2017 
Imaging index for fistulizing Crohn's
 08 August 2017 
Statin use after colon cancer
 07 August 2017 
Contraindications of biologic therapies in IBD
 07 August 2017 
Predicting clinical outcome in colorectal cancer
 07 August 2017 
Future burden of esophageal cancer
 04 August 2017 
Internet decision-making resources for ulcerative colitis surgery
 04 August 2017 
Distal findings and proximal colorectal neoplasia
 04 August 2017 
CT colonography vs flexible sigmoidoscopy
 03 August 2017 
Bloating and abdominal distension
 03 August 2017 
Predictors of colectomy in ulcerative colitis
 03 August 2017 
Treatment for sensitized transplant patients
 02 August 2017 
Preventing reactivation of Hep B
 02 August 2017 
Improving medication adherence in IBD
 02 August 2017 
Multiply recurrent C. difficile in the USA
 01 August 2017 
Coping with IBD
 01 August 2017 
Hepatocellular carcinoma in autoimmune hepatitis
 01 August 2017 
Anti-TNF treatment in Crohn's disease
 31 July 2017 
Global HCV incidence and mortality elimination targets
 31 July 2017 
Diagnosing GERD
 31 July 2017 
Diagnostic accuracy of severe liver fibrosis in patients with NAFLD
 28 July 2017 
Low FODMAP diet in IBS
 28 July 2017 
IBD patient–centered medical home
 28 July 2017 
Excluding NAFLD in the general population
 27 July 2017 
H. pylori infection and preeclampsia
 27 July 2017 
Colorectal cancer increases in developed and developing regions
 27 July 2017 
Anger in HIV-HCV co-infected patients
 26 July 2017 
Treating chronic pancreatitis
 26 July 2017 
Colorectal cancer screening
 26 July 2017 
Factors that influence H. pylori gastritis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us